Antibody (2)Cell (1)
En ligne (3)
Mouse (2)Human (1)
- (3)
PE Labeled (1)APC Labeled (1)- (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
CJUR-STF299 | Jurkat | Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) | |||||
CDA-AFM785 | HEK293 | APC-Labeled Monoclonal Anti-CD16a Antibody, Mouse IgG1 (3H8B10) (0.03% Proclin) | |||||
CDA-PFM785 | HEK293 | PE-Labeled Monoclonal Anti-CD16a Antibody, Mouse IgG1 (3H8B10) (0.03% Proclin) |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Siplizumab | MEDI-507; TCD-601 | Phase 2 Clinical | Catholic University Of Louvain, Itb-Med Llc | Multiple Myeloma; Amyotrophic Lateral Sclerosis; Kidney Failure, Chronic; Plaque psoriasis; Anemia, Sickle Cell; Lymphoma; Lymphoma, T-Cell; Hidradenitis Suppurativa; Hepatitis, Autoimmune; Lymphoma, Extranodal NK-T-Cell; Psoriasis; Cholangitis, Sclerosing; Diabetes Mellitus, Type 1; Liver Diseases; Myelodysplastic Syndromes; Neoplasms; Graft vs Host Disease; Kidney Diseases; Liver Cirrhosis; Renal Insufficiency; Rejection of liver transplantation; Leukemia; End Stage Liver Disease; Rejection of renal transplantation | Details |
| Alefacept | LFA-3-TIP; LFA-3(92)IgG; BG-9273; BG-9712; ASP-0485 | Phase 1 Clinical | Astellas Pharma Inc | Diabetes Mellitus, Type 1; Graft vs Host Disease; Psoriasis; Anemia, Aplastic; Lymphoma | Details |
| SBT-11-5301 | SBT115301 | Phase 1 Clinical | Sonoma Biotherapeutics Inc | Autoimmune Diseases | Details |
| PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute | Details |




